Dyadic International, Inc. (OTCQX: DYAI): Managing Director, Biz Dev/Licensing | Stock News Now Video
SNNLive caught up with Matthew Jones, Managing Director of Business Development and Licensing of Dyadic International, Inc. (OTCQX: DYAI) at the Dawson James Small Cap Growth Conference 2016 in Jupiter, FL. For more information about Dyadic International, Inc., please visit: http://www.dyadic.com/ The interview may contain forward looking statements about Dyadic International, Inc. See Dyadic International's periodic filings with the Securities and Exchange Commission for more complete information. About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical protein production system based on the fungus Myceliopthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, production and performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research & development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in developing and manufacturing biopharmaceuticals which these technologies help produce. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly saving lives. Subscribe NOW to Stock News Now: http://bit.ly/1Q5Yfym New videos are added almost every day to the Stock News Now channel sharing fascinating stories and companies from the MicroCap stock market. Get more Stock News Now: Website: http://stocknewsnow.com/ Follow Stock News Now: https://twitter.com/StockNewsNow Like Stock News Now: https://www.facebook.com/SnnInc/ Follow Stock News Now on LinkedIn: https://www.linkedin.com/company/stoc... Follow Stock News Now on StockTwits: http://stocktwits.com/StockNewsNow StockNewsNow.com, The Official MicroCap News Source, is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, Wall Street Views, SNNLive Newscasts, as well as, MicroCap Review magazine articles, guest submissions, and the latest news and headlines from MicroCap companies. Users can engage directly and share the information provided through social media. Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.